RaySearch, a medical technology company, announces that RayStation 9 has been granted regulatory clearance in China – a significant growth market for RaySearch. The approval will bring notable additional features to cancer centers in the country, including Plan Explorer, support for planning of Accuray Radixact and TomoTherapy treatment delivery systems, as well as a wide range of system-wide improvements.
Chinese customers have high demands for efficient and flexible radiation therapy solutions. These requirements drives a high interest in RayStation, which combines the ultimate user experience with advanced functionality, support for a broad range of machines, leading automation features, and very high calculation speeds.
This regulatory clearance is major step forward for RaySearch in terms of its offering to customers in China.
RaySearch has local presence with its own subsidiary in China since 2017 and registers a growing demand for RayStation from Chinese customers. Currently, there are around 60 customers for RayStation in the country.
Johan Löf, founder and CEO, RaySearch, says: “The unique features of RayStation 9 will now be available to centers across China. The Chinese market offers significant growth opportunities for RaySearch and by this regulatory clearance we can meet the needs of more centers in the country.”
RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system (TPS) and the oncology information system (OIS) RayCare.
RayStation is a flexible, innovative treatment planning system, chosen by many of the leading cancer centers worldwide.
